General Spectrum of Activity
Candida infections both mucocutaneous and invasive - i.e. Candidemia.
Antifungal prophylaxis in immunocompromised patients.
Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity. Target therapeutic level 2 or greater, target level to minimize toxicity is < 5.5.
QTc interval in patients at elevated risk.
Monitor hepatic profile.
Hepatic enzyme abnormalities
Rash - up to 20%
CYP450 interactions ++.
Other QTc prolonging agents.
Recommend review of pt medications due to high frequency of significant interactions.
Antimicrobial class: Triazole antifungal, Second generation
Pregnancy category: D
Urine penetration: Poor
Lung penetration: Therapeutic
CSF penetration: Therapeutic